ERBB2 and breast carcinoma: In addition, the developed bioplatform made possible the direct assessment of ErbB2 status in intact breast cancer cells, thus demonstrating that the new magnetoimmunosensing bioscaffold constitutes a useful and truthful analytical tool in the diagnosis of breast cancer by either ErbB2 protein determination in serum or detection of breast cancer cell status.